Can-Fite Biopharma Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $405K-39.9% YoYTTM through 31 Dec 2025
Net Income -$9.8MTTM through 31 Dec 2025
Free Cash Flow -$9MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -2,456.8% |
| Net Margin | -2,426.7% |
Returns
-175.8%ROE
-103.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.46x
Net Debt-$8.5Mnet cash position
Cash & Equivalents$5.5M
Quality Metrics
Altman Z-Score-27.76
Piotroski F-Score2 / 9
FCF Margin-2,210.1%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $405K
Diluted EPS-$5.97TTMFY2025: $-5.97
Dividend
No dividend
Capital Allocation
Capex Intensity0.5%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.